A Phase I, Open-Label, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of DMUC-4064A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer

Trial Profile

A Phase I, Open-Label, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of DMUC-4064A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Sep 2016

At a glance

  • Drugs RG 7882 (Primary)
  • Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 01 Dec 2015 Planned End Date changed from 1 Nov 2017 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
    • 01 Dec 2015 Planned primary completion date changed from 1 Nov 2017 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
    • 01 Oct 2015 Planned End Date changed from 1 Dec 2017 to 1 Nov 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top